Benefit of statins in daily practice? A six-year retrospective observational study

Pharmacological Research

Volumn 60, Issue 5, 2009, Pages 397-401

  Deambrosis, P ^a,b   Terrazzani, G ^a   Walley, T ^c   Bader, G ^b   Giusti, P ^b   Debetto, P ^b   Chinellato, A ^a  

^a Local Health Authority ULSS 9   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adherence; Cholesterol; Effectiveness; Efficacy; Guideline; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 69549118433     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.06.009     Document Type: Article

References (29)

1. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., and Furberg C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97 10 (1998) 592-946
2. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 24 (1999) 2340-2346
3. Pignone M., Phillips C., and Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 321 7267 (2000) 983-986
4. Cheung B.M., Lauder I.J., Lau C.P., and Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57 5 (2004) 640-651
5. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
6. Stalenhoef A.F. Scandinavian simvastatin study (4S). Lancet 344 8939-8940 (1994) 1766-1767 author reply 1767-1768
7. Pfeffer M.A., Sacks F.M., Moyé L.A., Brown L., Rouleau J.L., Hartley L.H., et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 76 9 Suppl. 1 (1995) 98C-106C
8. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 76 9 (1995) 113C-117C
9. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20 10 (1999) 725-741
10. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359 9315 (2002) 1379-1387
11. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 332 17 (1995) 1125-1131
12. Deambrosis P., Sramin C., Terrazzani G., Scaldaferri L., Debetto P., Giusti P., et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharm 63 2 (2007) 197-203
13. Wei L., Wang J., Thompson P., Wong S., Struthers A.D., and MacDonald T.M. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 88 3 (2002) 229-233
14. Blackburn D.F., Dobson R.T., Blackburn J.L., and Wilson T.W. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 25 8 (2005) 1035-1043
15. Bouchard M.H., Dragomir A., Blais L., Bérard A., Pilon D., and Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63 6 (2007) 698-708
16. Grant R.W., O'Leary K.M., Weilburg J.B., Singer D.E., and Meigs J.B. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 164 21 (2004) 2343-2348
17. Huser M.A., Evans T.S., and Berger V. Medication adherence trends with statins. Adv Ther 22 2 (2005) 163-171
18. Mantel-Teeuwisse A.K., Goettsch W.G., Klunge O.H., de Boer A., and Herings R.M. Long term persistence with statin treatment in daily medical practice. Heart 90 9 (2004) 1065-1066
19. Hughes D.A., and Walley T. Predicting real world effectiveness by integrating adherence and pharmacodynamic modelling. Clin Pharmacol Ther 74 (2003) 1-8
20. Hughes D.A., Bagust A., Haycox A., and Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 19 (2001) 1185-1197
21. Programma Nazionale Linee Guida (accessed July 24, 2007 at http://wwwpnlgit/LG/005colest/0-basehtm).
22. Ramsay L.E., Yeo W.W., and Jackson P.R. Ischaemic heart disease and cholesterol Effective diets are unpalatable. BMJ 308 (1994) 1038-1041
23. Genest J., McPherson R., Frohlich J., and Fodor G. The analysis by Manuel and colleagues creates controversy with the headline, not data. CMAJ 172 8 (2005) 1033-1034
24. Benner J.S., Pollack M.F., Smith T.W., Bullano M.F., Willey V.J., and Williams S.A. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 62 14 (2005) 1468-1475
25. Goettsch W.G., YinDD, Alemao E., Klungel O.H., Stalenhoef A.F., and Herings R.M. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 20 7 (2004) 1025-1033
26. Abraha I., Montedori A., Stracci F., Rossi M., and Romagnoci C. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 59 8-9 (2003) 659-661
27. Abramson J., and Wright J. Are lipid-lowering guidelines evidence-based?. Lancet 369 (2007) 168-169
28. Walsh J.M.E., and Pigame M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
29. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360 (2002) 1623-1630